Calidi Biotherapeutics Inc. (CLDI) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

• Price: $0.82
• Market Cap: $5.88M
• P/E Ratio: 2.28
• EPS: $0.36
• 52-Week High: $13.20
• 52-Week Low: $0.72

Market Sentiment

Calidi Biotherapeutics Inc. currently has a Bullish sentiment score of 0.30.

About Calidi Biotherapeutics Inc.

Calidi Biotherapeutics, Inc. (CLDI), based in San Diego, California, is a pioneering clinical-stage biotechnology company dedicated to advancing innovative immunotherapies for cancer treatment. Leveraging its proprietary platform of genetically modified oncolytic viruses, Calidi targets cancer cells with precision while simultaneously boosting the body’s immune response against tumors. With a robust pipeline of promising clinical trials and a firm commitment to addressing critical unmet medic...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Calidi Biotherapeutics Inc. and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CLDI pay dividends?

Calidi Biotherapeutics Inc. (CLDI) does not currently pay a regular dividend.

What is CLDI's P/E ratio?

Calidi Biotherapeutics Inc. has a price-to-earnings (P/E) ratio of 2.28.

What is CLDI's market cap?

Calidi Biotherapeutics Inc. (CLDI) has a market capitalization of $5.88M with a current stock price of $0.82.